+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
FEMALE
ID07667192

International Patient Registry Observing Reirradiation and Total Ablative Treatments for Recurrent Gynecologic Cancers

Led by Affidea Nu-med Center of Oncological DIagnostics and Therapy · Updated on 2026-10-16

500

Participants Needed

1

Research Sites

261 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting an international, multicenter patient registry to observe adults with recurrent gynecologic cancers who have previously received radiotherapy and are treated or planned for reirradiation andor total ablative strategies. The study focuses on collecting data without assigning any treatments, aiming to understand real-world outcomes after these treatment approaches. The registry includes patients with various gynecologic malignancies such as uterine, cervical, vaginal, vulvar, ovarian, fallopian tube, primary peritoneal, and other rare types, who have recurrent or progressive disease and prior radiotherapy history. Participants receive treatments chosen by their local healthcare teams based on routine clinical care, which may include reirradiation modalities like brachytherapy, external-beam radiotherapy, stereotactic body radiotherapy, proton therapy, or intraoperative radiotherapy. Total ablative strategies may involve combinations of radiotherapy, surgery, ablation, systemic therapy, or other metastasis-directed therapies. The registry gathers both retrospective and prospective data, covering patients treated before or after the registry started, without altering or delaying any clinical decisions. During the study, data on patient demographics, tumor characteristics, prior treatments, recurrence details, treatment exposures, responses, progression, survival, adverse events including severe toxicities and fistula events, and patient-reported outcomes are collected. Outcomes like radiographic progression-free survival, overall survival, and treatment-related adverse events are monitored for up to five years. The registry captures a comprehensive dataset reflecting real-world clinical practice, with follow-up evaluations and quality-of-life assessments where available.

CONDITIONS

Brief Title

Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer

Research Team

M

Mateusz Bilski, Md, PhD

P

Paulina Kleban, MGR

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here